In a groundbreaking advancement for prostate cancer treatment, researchers led by Radboud University Medical Center (Radboudumc) have unveiled promising results demonstrating the efficacy of a novel therapeutic approach known as PSMA-targeted radioligand therapy in men with early-stage metastatic prostate cancer. Previous studies had firmly established that this therapy could extend survival in patients with advanced, treatment-resistant prostate cancer. However, for the first time, this research indicates that administering PSMA therapy at an earlier disease stage can safely delay the initiation of more aggressive hormone therapies by nearly twenty months, heralding a potential paradigm shift in managing this common and challenging malignancy.
Prostate cancer remains one of the most frequently diagnosed cancers among men worldwide, with approximately 15,000 new cases annually in the Netherlands alone. Standard treatment modalities—including surgery, radiation therapy, chemotherapy, and androgen deprivation therapy (ADT)—have significantly improved outcomes but often come with burdensome side effects and quality-of-life implications. PSMA therapy, which employs a radioactively labelled molecule ([177Lu]-PSMA-617) targeting the prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells, offers a unique internal radiotherapy that delivers cytotoxic radiation directly to cancerous sites while sparing healthy tissue.
The latest study focused on patients with oligometastatic hormone-sensitive prostate cancer, defined by the presence of up to five metastatic lesions. This patient population represents a critical window for intervention, where delay or modification of systemic therapies can drastically influence long-term disease trajectory and patient well-being. Conducted as a randomized, open-label phase 2 trial, the research enrolled 58 men who had undergone standard localized treatments, including surgery or targeted radiotherapy, but had not yet commenced conventional hormone therapies.
Participants were split evenly into two arms: one group received immediate PSMA-targeted radioligand therapy post-local treatment, while the control group was observed until disease progression and then treated with PSMA therapy. The experimental protocol consisted of four treatment cycles of [177Lu]-PSMA-617, meticulously dosed to optimize therapeutic effect while minimizing toxicity. All subjects were monitored for at least two years, allowing robust longitudinal assessment of treatment impact.
A striking divergence in disease progression emerged between the two groups. In the cohort receiving upfront PSMA therapy, only 52% showed disease progression by 27 months, compared to an alarming 97% in the control group. Moreover, initiation of subsequent hormone therapy—a standard but often debilitating intervention—was deferred by an average of twenty months among those treated early with PSMA radioligand therapy. This delay not only defers associated side effects, such as hot flashes, muscle weakness, and profound fatigue frequently likened to menopausal symptoms, but also preserves patients’ quality of life during a critical phase of their illness.
Notably, the therapy was well-tolerated, with minimal adverse events reported, reinforcing its safety profile. According to Dr. James Nagarajah, Nuclear Medicine Physician and principal investigator, these findings address a significant unmet clinical need. Patients increasingly seek alternatives to hormone therapy due to its impact on physical and psychological health. By offering a targeted radiation approach that effectively controls disease progression, PSMA therapy provides a compelling adjunct or perhaps future alternative to systemic hormone suppression.
Another remarkable observation was the potential of PSMA therapy to convert patients back to eligibility for localized treatments. Bastiaan Privé, the study’s first author, emphasized that in some cases, the therapy substantially reduced tumor burden, enabling patients to receive additional rounds of targeted radiation. This cyclical therapeutic strategy could further extend periods free from systemic hormone therapy, maximizing disease control while minimizing cumulative toxicity.
These results, recently published in the prestigious journal The Lancet Oncology, not only advance the scientific understanding of prostate cancer biology and therapeutic response but also open new avenues for clinical decision-making. As researchers deepen exploration into the optimal timing, dosing, and combination strategies for PSMA radioligand therapy, patient-centered outcomes remain at the forefront, balancing efficacy with quality of life considerations.
The implications of this work extend beyond immediate clinical application. The concept of targeting cancer with radiolabeled ligands against specific cell surface markers embodies a paradigm shift towards precision oncology—an era where treatments are increasingly personalized based on tumor biology rather than relying solely on traditional systemic therapies. This trial exemplifies how integrating molecular imaging and targeted therapeutics can revolutionize prostate cancer management, potentially applicable to other malignancies expressing unique molecular targets.
While the study’s sample size limits broad generalization, the compelling efficacy signals warrant larger-scale trials to confirm these findings and elucidate long-term survival benefits. The multi-institutional collaboration, including participation from prominent centers such as Amsterdam UMC and UMCG, underscores the scientific rigor and translational potential of this innovative treatment strategy.
In summation, PSMA-targeted radioligand therapy emerges as a transformative approach for men with limited metastatic prostate cancer, effectively delaying the onset of hormone therapy and preserving quality of life. This adds a powerful new weapon to the oncologist’s arsenal, offering hope to patients seeking less invasive yet highly efficacious treatment options. Continued research is poised to refine and expand this therapeutic modality, moving toward an era where prostate cancer can be managed with precision, minimizing toxicity, and maximizing survival.
As the scientific community digests these findings, the message is clear: targeting prostate cancer cells with radiolabeled molecules not only extends survival but also enhances patients’ lived experience by alleviating the hardships of conventional hormone treatments. This harmonizes with modern oncology’s overarching goals—achieving optimal treatment outcomes while safeguarding quality of life. The advent of PSMA radioligand therapy marks a turning point that could soon transform clinical practice guidelines and patient care worldwide.
Subject of Research: People
Article Title: [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
News Publication Date: 30-Mar-2026
Image Credits: Source: Radboudumc
Keywords: Prostate cancer, Medical treatments, Clinical trials, Drug studies
